BridgeBio Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BBIO and other ETFs, options, and stocks.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. 

CEO
Neil Kumar
CEONeil Kumar
Employees
839
Employees839
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2015
Founded2015
Employees
839
Employees839

BBIO Key Statistics

Market cap
12.98B
Market cap12.98B
Price-Earnings ratio
-18.60
Price-Earnings ratio-18.60
Dividend yield
—
Dividend yield—
Average volume
2.50M
Average volume2.50M
High today
$67.40
High today$67.40
Low today
$65.26
Low today$65.26
Open price
$67.03
Open price$67.03
Volume
2.06M
Volume2.06M
52 Week high
$93.42
52 Week high$93.42
52 Week low
$52.75
52 Week low$52.75

Stock Snapshot

As of today, BridgeBio Pharma(BBIO) shares are valued at $66.35. The company's market cap stands at 12.98B, with a P/E ratio of -18.60.

On 2026-10-17, BridgeBio Pharma(BBIO) stock traded between a low of $65.26 and a high of $67.40. Shares are currently priced at $66.35, which is +1.7% above the low and -1.6% below the high.

BridgeBio Pharma(BBIO) shares are trading with a volume of 2.06M, against a daily average of 2.5M.

During the past year, BridgeBio Pharma(BBIO) stock moved between $52.75 at its lowest and $93.42 at its peak.

During the past year, BridgeBio Pharma(BBIO) stock moved between $52.75 at its lowest and $93.42 at its peak.

BBIO News

TipRanks 3d
BridgeBio Pharma assumed with a Buy at UBS

UBS assumed coverage of BridgeBio Pharma (BBIO) with a Buy rating with a price target of $92, up from $82. The Street underestimates the company’s lead drug Att...

Simply Wall St 3d
Should Late Stage Pipeline Progress Require Action From BridgeBio Pharma Investors?

BridgeBio Pharma reported fresh clinical and real world data across several late stage programs, including acoramidis in ATTR-CM, encaleret in ADH1 and chronic...

Should Late Stage Pipeline Progress Require Action From BridgeBio Pharma Investors?
TipRanks 4d
BridgeBio Wins FDA Priority Review for Infigratinib

BridgeBio Pharma ( (BBIO) ) just unveiled an announcement. On October 6, 2026, BridgeBio Pharma reported that the U.S. Food and Drug Administration accepted an...

Analyst ratings

92%

of 24 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

More BBIO News

Simply Wall St 5d
BridgeBio Pharma Gains Clinical Momentum, Is The Upside Already Priced In?

BridgeBio Pharma (BBIO) has just packed several important clinical and regulatory updates into a short window, including fresh real-world data for acoramidis in...

BridgeBio Pharma Gains Clinical Momentum, Is The Upside Already Priced In?

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.